May 22, 2018 : DCMS #398

DISASTERS AVERTED — Near Miss Case Studies

Once a Pump, Always a Pump? Wrong!

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

George Bakris Part 5, High Blood Pressure and Diabetes

HOMERUN SLIDES — Great Clinical Presentation Highlights

Prediabetes Part 1

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #126: Beta-Cell Mass and Function in Human Type 2 Diabetes Part 2

MOST POPULAR ARTICLES OF THE MONTH

#1 American College of Physicians Misses A1C Target
#2 Know the Difference When Choosing Between CGMs
#3 Everything You Need To Know To Prescribe An SGLT-2 Inhibitor (Part 1)

We preach good health, lean body muscle mass, exercise, and weight control to our patients, but at times we actually have patients who do too good a job. A good example of this can be seen in this week’s Disaster Averted. Our patient, the picture of perfect health and body composition, was having erratic glucose levels while using a patch pump. Our own medical editor, Joy Pape, FNP-C, CDE, helped this patient discover solutions to these erratic readings. Click here to find out what she did.

Dave Joffe

Editor-in-chief

A man, lean and muscular, with type 1 for over 25 years, has been pumping for 15 years and wearing a sensor for the past five years. Glucose levels have been very erratic. We checked his sites and were concerned that the erratic glucose levels were mostly related to lack of subcutaneous fat and scar tissue, so he was actually getting insulin into his muscle, scar tissue, or subcutaneous tissue at various times. Also, the patient wears an OmniPod and thought it could only be in one particular direction.

Dr. George Bakris explains the new ADA blood pressure guidelines in a talk with Diabetes in Control Publisher Steve Freed during the ADA 77th Scientific Session in San Diego.

In part 1 of this 2-part Homerun Slides series, screening and monitoring prediabetes.

The role of beta-cell death and regeneration: The loss of beta-cells in T2DM has been mainly attributed to increased beta-cell death due to apoptosis and other forms of cell death, possibly driven by adverse environmental conditions and probably mediated by several intracellular mechanisms. Apoptosis is a type of programmed cell death morphologically characterized by cell rounding up, bleb formation and chromatin condensation. As a matter of fact, in autoptic pancreatic samples apoptosis has been shown to be significantly increased in both obese and lean type 2 diabetic cases as compared to BMI-matched, nondiabetic controls.

By Stanley S. Schwartz, MD and Mary E Herman, PhD

Despite guidelines, hypoglycemia can largely be avoided without shortchanging tight glucose control.

You may wonder which CGM monitor is best for your patients. I know I do.

Learn from Dr. Stephen W. Ponder, MD, FAAP, CDE-AADE Educator of the Year, Board Certified Pediatric Endocrinologist, Pediatric Residency Program Director at Baylor Scott & White McLane Children’s Hospital and 50 year Joslin Medalist. He also helps people with diabetes through the “sugar surfing” method to empower individuals who have diabetes to live fuller and more satisfying lives.

Why and when to use this therapy to treat patients who have type 2 diabetes.